Prospective cohort study on novel blood markers in hepatocellular carcinoma
Not Applicable
- Conditions
- hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000031562
- Lead Sponsor
- Yokohama City University School of Medicine Department of Gastroenterology and Hepatology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
1) Persons judged inappropriate for this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To elucidate the blood marker in diagnosis of hepatocellular carcinoma by proteomics analysis, metabolomics analysis, and miRNA analysis using serum and plasma of patients with hepatocellular carcinoma.
- Secondary Outcome Measures
Name Time Method 1) To elucidate the blood marker in diagnosis of hepatocellular carcinoma by individual protein expression analysis and individual miRNA analysis using serum and plasma of patients with hepatocellular carcinoma. 2) Abdominal skeletal muscle mass analysis using CT/MRI image at diagnosis of hepatocellular carcinoma
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are targeted by novel blood markers in hepatocellular carcinoma progression?
How do novel blood markers in JPRN-UMIN000031562 compare to alpha-fetoprotein for HCC diagnosis accuracy?
Which biomarkers identified in JPRN-UMIN000031562 predict early recurrence in hepatocellular carcinoma patients?
Are there specific biomarkers in JPRN-UMIN000031562 associated with treatment resistance in HCC subtypes?
What are the current therapeutic targets in HCC related to the blood markers studied by Yokohama City University?